BIO-Europe Spring® 2017: Mitochondrial medicine focus drives NeuroVive orphan ambitions

April 24, 2017
Underpinned by a profound understanding of genetic mitochondrial disorders, Swedish biotech NeuroVive Pharmaceutical AB is pursuing a two-pronged orphan and speciality pharma approach. CEO Erik Kinnman spoke with Scrip’s Mike Ward and explained how the company is looking for partners for its NASH and hepatocellular cancer programs but intends to develop its own orphan treatments.
Previous Video
BIO-Europe Spring® 2017: Imanova trims Phase I and IIa trial timelines and costs
BIO-Europe Spring® 2017: Imanova trims Phase I and IIa trial timelines and costs

Dr. Kevin Cox, CEO of Imanova, the UK-based translational biomedical imaging company, explains to Scrip’s M...

Next Video
BIO-Europe Spring® 2017: vitalityDNA plans to keep healthy individuals healthy
BIO-Europe Spring® 2017: vitalityDNA plans to keep healthy individuals healthy

Precision medicines, an increased interest in the microbiome and a growing focus on wellness are some of th...